




RealRate

PHARMACEUTICAL 2012

Alaunos Therapeutics Inc
Rank 141 of 196

ALAUNOS[™]
THERAPEUTICS



The relative strengths and weaknesses of Alaunos Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alaunos Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 12% points. The greatest weakness of Alaunos Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is 139%, being 95% points below the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	106,105
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,363
Liabilities, Non-Current	19,425
Other Assets	862
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	3,713
Other Net Income	9,435
Other Revenues	667
Property and Equipment	1,141
Research and Development	128,899
Selling, General and Administrative Expense	68,795

Output Variable	Value in 1000 USD
Assets	108,108
Liabilities	36,501
Expenses	197,694
Revenues	667
Stockholders Equity	71,607
Net Income	-187,592
Comprehensive Net Income	-187,592
BaseVar	176,202
ECR before LimitedLiability	-44%
Economic Capital Ratio	139%